[Sperm parameters in male idiopathic infertility after treatment with prelox].
The diagnosis of male infertility is determinate after assessment of sperm quality and clinical study. In nearly 30% of the cases nevertheless detailed clinical and laboratory study it can't be discovered the cause and on the bases of exclusion criteria set the diagnosis idiopathic infertility. The object of our study was investigation of the group patients (n=50) with idiopathic infertility treated with Prelox and to be studied its effects on spermatozoa parameters.


METHODS
The study design was double-blind, placebo-controlled, cross-over, randomized study, including introduction period (1 month), two therapeutic periods (each one of 1 month) separated with 1 month wash out period and concluding period of 1 month. There was applied a new method for treatment with mechanism of action stimulation the production cGMP of spermatozoa endothelial nitric oxide synthase (eNOS). This is not surprising achieving results show improvement of sperm quality. The methods of the study were: 1. Assessment of the conventional semen analysis (according the criteria of WHO, 1999). 2. Spermatozoa function tests. 3. Spermatozoa-cervical mucus penetration tests.


RESULTS
The obtained results showed improvement of sperm quality, in the middle-aged men the therapeutic answers was better than in younger. In conclusion the therapy with Prelox improve sperm parameters in men with idiopathic infertility. Pycnogenol (one of the constituents of Prelox) has powerful antioxidative influence ameliorating spermatozoa function.
Nikolova
V
V
Stanislavov
R
R
Vatev
I
I
Nalbanski
B
B
Pŭnevska
M
M
D000328:Adult; D001120:Arginine / Q000008:administration & dosage / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism; D004311:Double-Blind Method; D004338:Drug Combinations; D005419:Flavonoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007248:Infertility, Male / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010936:Plant Extracts; D013075:Sperm Capacitation / Q000187:drug effects; D013094:Spermatozoa / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D016896:Treatment Outcome
D004338:Drug Combinations; D005419:Flavonoids; D010936:Plant Extracts; C024070:pycnogenols; D001120:Arginine; D052250:Nitric Oxide Synthase Type III; D006152:Cyclic GMP